Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Pacritinib |
Synonyms | |
Therapy Description |
Pacritinib (SB1518) is an inhibitor of JAK2 and FLT3, with activity against JAK2 V617F and FLT3 ITD, which potentially increases tumor cell apoptosis, induces cell cycle arrest, and decreases tumor growth (PMID: 22829080, PMID: 21691275). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pacritinib | Vonjo | SB1518|SB-1518|SB 1518 | FLT3 Inhibitor 57 JAK2 Inhibitor - ATP competitive 15 | Vonjo (pacritinib) is an inhibitor of JAK2 and FLT3, with activity against JAK2 V617F and FLT3 ITD, which potentially increases tumor cell apoptosis, induces cell cycle arrest, and decreases tumor growth (PMID: 22829080, PMID: 21691275). Vonjo (pacritinib) is FDA approved for use in patients with primary or secondary myelofibrosis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins JAK2 V617F | hematologic cancer | predicted - sensitive | Pacritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vonjo (pacritinib) treatment decreased cell proliferation and downstream signaling in transformed hematologic cells expressing a FLT3-ITD mutation and JAK2 V617F in culture but may not be capable of fully inhibiting Flt3 and Jak signaling at clinically achievable concentrations (PMID: 33149267). | 33149267 |
FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | Pacritinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Vonjo (pacritinib) induced apoptosis and inhibited proliferation of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture, and inhibited tumor growth and induced tumor regression in cell line xenograft models (PMID: 22829080). | 22829080 |
FLT3 exon 14 ins JAK3 V722I | hematologic cancer | decreased response | Pacritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vonjo (pacritinib) treatment decreased cell proliferation and Akt and Erk phosphorylation, but did not fully inhibit Stat5 phosphorylation in transformed hematologic cells expressing a FLT3-ITD mutation and JAK3 V722I and was less effective compared to treatment with the combination of a FLT3 inhibitor and a JAK inhibitor in culture (PMID: 33149267). | 33149267 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04858256 | Phase II | Pacritinib | Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Not yet recruiting | USA | 0 |
NCT04635059 | Phase II | Pacritinib | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer (BLAST) | Recruiting | USA | 0 |
NCT03601819 | Phase I | Pacritinib | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Terminated | USA | 0 |
NCT03165734 | Phase II | Lenalidomide Ruxolitinib Hydroxyurea Pacritinib Thalidomide | A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 13 |
NCT02277093 | Phase II | Pacritinib | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | Terminated | USA | 0 |
NCT02469415 | Phase II | Decitabine Azacitidine Pacritinib | Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | Terminated | USA | 0 |
NCT02251821 | Phase II | Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide | JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | Recruiting | USA | 0 |
NCT03645824 | Phase II | Pacritinib | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF) | Recruiting | BEL | 1 |